REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, "Sustainable API Manufacturing" at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics. Codexis is a leading enzym ...

Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Carrie McKim - Director, Investor Relations Stephen Dilly - President & Chief Executive Officer Stefan Lutz - Senior Vice President, Research Kevin Norrett - Chief Operating Officer Sri Ryali - Chief Financial Officer Conference Call Participants Matt Stanton - Jefferies Evan Stampler - Stifel Matt Hewitt - Craig-Hallum Operator Welcome to the Codexis' First Quarter 2024 Earnings Call. [Operator Instruct ...

| --- | --- | --- | |------------------------------|-------|----------------------| | | | | | | | | | | | | | May 2, 2024 Q1 2024 Results | | | | | | We engineer enzymes | 1 Actual results could differ materially from Codexis' current expectations for a variety of reasons, including due to the factors set forth in Codexis' most recently filed periodic report, including under the caption "Risk Factors," and Codexis' other current and periodic reports filed with the SEC. If any of these risks or uncertainties ...

• We use hazardous materials in our business, and we must comply with environmental laws and regulations. • We may be involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful. Biotherapeutic programs are highly regulated and expensive, and our enzyme products are complex and subject to quality control requirements. The ability of our customers, future customers or collaborators, including any company developing RNAi therapeutics, ...

Exhibit 99.1 Codexis Reports First Quarter 2024 Financial Results Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 2, 2024 -- Codexis, Inc. (NASDAQ: CDXS), a leading ...

REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company's Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications. Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufactu ...

Codexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Carrie McKim - Director of IR Stephen Dilly - President and CEO Kevin Norrett - COO Sri Ryali - CFO Stefan Lutz - SVP of Research Conference Call Participants Brandon Couillard - Jefferies Evan Stampler - Stifel Steven Mah - TD Cowen Jacob Johnson - Stephens Matthew Hewitt - Craig-Hallum Capital Group Operator Welcome to the Codexis Fourth Quarter and Full Year 2023 Earnings Conference Call. [Opera ...

Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 112.50%. A quarter ago, it was expected that this producer of custom industrial enzymes would post a loss of $0.32 per share when it actually produced a loss of $0.26, delivering a surprise of 18.75%.Over the last fo ...

In July 2022, we announced that we and Pfizer Inc. ("Pfizer") had entered into an agreement to supply Pfizer with CDX-616, a proprietary high-performance enzyme used to manufacture a critical intermediate for nirmatrelvir, an active pharmaceutical ingredient in PAXLOVID™, Pfizer's antiviral therapeutic, which is now approved in the United States for the treatment of mild-to-moderate COVID19 in people at high risk of progression to severe illness, and also authorized or approved by other regulatory authoriti ...

"We are thrilled with how we closed out 2023, and it's quite clear that the strategic decisions we made last year are translating into real momentum as we kick off 2024. We recently executed asset purchases for our lead biotherapeutics asset, CDX-7108, with Nestlé Health Science, and our newly engineered dsDNA ligase with Roche. We also completed an out-licensing deal with Aldevron for our Codex® HiCap RNA Polymerase to extend our commercial reach into the growing mRNA-based therapeutics market. Finally, we ...